NAI-802(NAI-802) - _专利_临床

概要

基本信息

药物类型

合成多肽

别名

variant actagardine lantibiotic(NAICONS)

靶点-

作用机制-

治疗领域

感染

在研适应症-

非在研适应症

革兰氏阳性细菌感染

原研机构

Naicons Srl

在研机构-

非在研机构

Naicons Srl

最高研发阶段无进展药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

序列信息

Sequence Code 530768368

关联

100 项与 NAI-802 相关的临床结果

登录后查看更多信息

100 项与 NAI-802 相关的转化医学

登录后查看更多信息

100 项与 NAI-802 相关的专利（医药）

登录后查看更多信息

1

项与 NAI-802 相关的文献（医药）

2013-02-01·The Journal of Antibiotics4区 · 医学

Isolation and characterization of NAI-802, a new lantibiotic produced by two different Actinoplanes strains

4区 · 医学

Article

作者: Eleonora Gaspari ; Sonia I Maffioli ; Stefano Donadio ; Matteo Simone ; Paolo Monciardini

Lantibiotics are biologically active peptides produced by Gram-positive bacteria. Starting from fermentation broth extracts preselected from a high-throughput screening program for discovering cell-wall inhibitors, we successfully isolated a new lantibiotic produced by Actinoplanes sp., designated as NAI-802. MS and NMR analysis together with explorative chemistry established that NAI-802 consists of 21 amino acids, 19 of which are identical to those present in the class II lantibiotic actagardine. Interestingly, NAI-802 carries one extra alanine and one extra arginine at the N- and C-termini, respectively. As expected from the overall higher positive charge, NAI-802 was slightly more active than actagardine against staphylococci and streptococci. Further improvement of its antibacterial activity was achieved by adding one additional positive charge through conversion of the C-terminal carboxylate into the corresponding basic amide. NAI-802 thus represents a novel promising candidate for treating Gram-positive infections caused by multidrug-resistant pathogens.

100 项与 NAI-802 相关的药物交易

登录后查看更多信息